Around half the products made at the Broomfield facility will be discontinued or divested says Novartis, blaming increased US generics competition and customer consolidation for the closure.
The global contract development and manufacturing organization (CDMO) has launched its Almac Pod service solution in the US after introducing it in Europe last year.
Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.
Nestle Health Science has licensed a protein engineering platform from Codexis in a $14m deal that includes an option to co-develop a phenylketonuria drug candidate called CDX-6114.
Depomed Inc. says supplies of the extended release version of Nucynta will be delayed as a result of damage to a Puerto Rico manufacturing plant caused by hurricane Maria.
CordenPharma will supply Pfizer with highly potent active pharmaceutical ingredients (HPAPIs) from the facility in Boulder once earmarked for closure by the Big Pharma firm.
Following the announced sale of AstraZeneca’s solid dose facility to Avara, the former outlines the Reims, France-based sites capabilities, and tells us why it is letting it go.
US-based medical device manufacturing plants could experience a 20% decrease in recalls if US FDA investigators inspect the facilities on a rotating schedule, according to a new study.
Merck KGaA will install a new aseptic filling line at its facility in Bari, Italy for multiple sclerosis drugs, fertility treatments and growth hormones.
The US FDA has finalised guidance supporting new technologies which look to modernise pharmaceutical manufacturing, such as 3D printing and continuous processing.
AmerisourceBergen (ABSG) has pleaded guilty to distributing misbranded injectable cancer drugs processed at an unregistered facility in Alabama and agreed to pay $260m (€220m).
Aurobindo Pharma Limited has received a Form 483 detailing two problems identified by US FDA inspectors who visited its Unit VI facility in in Chitkul Village, Andhra Pradesh, India.
Implementing ‘aggregation’ – the term used to describe pharmaceutical product unit-to-case hierarchy – is not mandatory in Europe, however industry delegates say there is incentive to push its adoption.
Recipharm has acquired a Spanish manufacturing plant and signed a supply deal with former owner Roche for a range of solid dose products worth €35m a year.
Ajinomoto Althea, Inc. has opened a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA.
Patheon is “better positioned” to serve clients following the Thermo Fisher Scientific Inc. acquisition, says CDMO president, whose initial focus will be integration.
Recipharm will make clinical trial capsules to support oncology candidate KAND567, a former AstraZeneca Fractalkine receptor inhibitor being developed by Kancera.
CordenPharma has completed development of an early development suite for highly potent, oral solid dosage products at its Plankstadt, Germany location.
Aging pharmaceutical manufacturing facilities have become a major concern as the industry tries to keep pace with advancements in technology while balancing costs.
US WorldMeds has teamed up with Catalent Pharma Solutions to manufacture lofexidine, an investigational drug designed to treat symptoms associated with opioid withdrawal.
The Parental Drug Association (PDA) is offering guidance to drug makers with ageing, sometimes non-compliant facilities, which it hopes will help combat drug shortages.
Clintec International has opened a centre of excellence for clinical research and quality assurance capabilities as part of its headquarters expansion in Glasgow, Scotland.
Pfizer, Merck & Co (known as MSD outside of North America) and GlaxoSmithKline (GSK) have come together to support the development of continuous manufacturing and bio-catalysis technologies in Singapore.
AMRI has been acquired by a private equity firm and has already begun its search for “the next couple of acquisitions,” says its CEO – and the shopping list is long.
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.
Ajinomoto Althea, Inc. has added a new aseptic fill/finish line in response to client's concerns regarding active pharmaceutical ingredient (API) manufacturing costs.
